Background: Statin therapy, specifically a lipophilic statin Pitavastatin (Livalo) in acute myocardial infarction (AMI) setting may play an important role by not only reducing LDL-cholesterol, but also through the pleiotrophic effects, especially in diabetic patients (pts). It is not clear whether Pitavastatin will impact on the angiographic and clinical outcomes of diabetes pts. Method: This study consisted of 802 consecutive AMI pts presented in 10 major percutaneous coronary intervention (PCI) centers in Korea from February 2007 to September 2009. Pitavastatin 2mg/day was routinely administered from the AMI presentation time. We investigated the changes of lipid profiles, biochemical markers at baseline, 1, 6 and 12 months, the clinical outcomes up to 1 year and adverse effects. Results: A total 699 pts (87.1%) were finished 12-month clinical follow up. The baseline clinical characteristics were not similar between the two groups. Diabetes group were older (62.9 짹 11.0 vs. 60.6 짹 12.7 years, p=0.01), more hypertension (60% vs. 40.7%, p<0.01), previous PCI (13.4% vs. 9.1%, p=0.07), multi-vessel disease (MVD, 68.2% vs. 49.9%, p<0.01) and left main lesion (LM, 5.2% vs. 1.8% , p<0.03). At 6 to 9 months, angiographic outcomes were similar between the two groups. At 12 months, total death, target vessel revascularization (TVR) and TVR-major adverse cardiac events (MACE) were higher in Diabetes group in univariate analysis (Table). However, after baseline adjustment by multivariate analysis, diabetes was an independent predictor of TVR-MACE (OR 2.042, 95% CI 1.063-3.924, p=0.32). Conclusion: Despite of worse baseline clinical characteristics of Diabetic group, major clinical outcomes of diabetic AMI pts who were exclusively treated with PCI and routine Pitavastatin were similar with those of non-diabetic AMI pts except TVR-MACE which remained higher in Diabetic group.